Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients-Reference-Cited by-同舟云学术

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

Published:2013-01-30 Issue:1 Volume:8 Page:e54522
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Ling-Zhi,Ramírez Jacqueline,Yeo Winnie,Chan Mei-Yi Michelle,Thuya Win-Lwin,Lau Jie-Ying Amelia,Wan Seow-Ching,Wong Andrea Li-Ann,Zee Ying-Kiat,Lim Robert,Lee Soo-Chin,Ho Paul C.,Lee How-Sung,Chan Anthony,Ansher Sherry,Ratain Mark J.,Goh Boon-Cher

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Histone deacetylase inhibitors;PA Marks;Adv Cancer Res,2004

2. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines;SG Gray;Int J Oncol,2004

3. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications;CS Mitsiades;Proc Natl Acad Sci,2004

4. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors;MJ Peart;Proc Natl Acad Sci,2005

5. Potential of histone deacetylase inhibitors for bladder cancer treatment;N Tanji;Expert Rev Anticancer Ther,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydrazides as Inhibitors of Histone Deacetylases;Journal of Medicinal Chemistry;2024-08-02

2. Histone deacetylase inhibitor RG2833 has therapeutic potential for Alzheimer’s disease in females;2023-12-26

3. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer;Cellular Oncology;2023-11-07

4. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer;Journal of Medicinal Chemistry;2023-09-03

5. Medicinal chemistry advances in targeting class I histone deacetylases;Exploration of Targeted Anti-tumor Therapy;2023-08-31